Literature DB >> 28736180

Retreatment With Osimertinib Following Pneumonitis.

Misako Nagasaka1, Shirish M Gadgeel2.   

Abstract

Entities:  

Keywords:  Drug-related pneumonitis; EGFR; NSCLC; Re-challenge post pneumonitis; T790M inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28736180     DOI： 10.1016/j.cllc.2017.06.017

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  9 in total

1.  Late-onset severe pneumonitis under osimertinib.

Authors:  Zulfiya Syunyaeva; Katharina Berghof; Diego Kauffmann-Guerrero; Jeremias Götschke; Amanda Tufman; Kathrin Kahnert
Journal:  AME Case Rep       Date:  2019-10-15

2.  Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.

Authors:  June Hong Ahn
Journal:  Thorac Cancer       Date:  2020-07-15       Impact factor: 3.500

3.  [Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report].

Authors:  Junjie Gu; Fan Bai; Lan Song; Yingyi Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-11-20

4.  Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.

Authors:  Hannah Lu; Jonathan Dowell
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Authors:  Hiroaki Kodama; Kazushige Wakuda; Michitoshi Yabe; Naoya Nishioka; Eriko Miyawaki; Taichi Miyawaki; Nobuaki Mamesaya; Takahisa Kawamura; Haruki Kobayashi; Shota Omori; Akira Ono; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Masahiro Endo; Toshiaki Takahashi
Journal:  Invest New Drugs       Date:  2020-09-21       Impact factor: 3.850

6.  Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.

Authors:  Shunichi Nishima; Akihiko Miyanaga; Sho Saito; Mizuki Yuasa; Satoshi Takahashi; Takeru Kashiwada; Teppei Sugano; Rintaro Noro; Yuji Minegishi; Yasuhiro Terasaki; Yoshinobu Saito; Kaoru Kubota; Masahiro Seike; Akihiko Gemma
Journal:  Intern Med       Date:  2020-09-30       Impact factor: 1.271

7.  Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies.

Authors:  Christiane Bickert; Kathrin Kahnert; Diego Kauffmann-Guerrero; Jeremias Götschke; Zulfiya Syunyaeva; Jürgen Behr; Amanda Tufman
Journal:  Ther Adv Med Oncol       Date:  2021-06-10       Impact factor: 8.168

8.  Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.

Authors:  Shingo Satoh; Takayuki Shiroyama; Motohiro Tamiya; Shingo Nasu; Ayako Tanaka; Satomu Morita; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Tomonori Hirashima
Journal:  Respir Med Case Rep       Date:  2017-12-11

9.  Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.

Authors:  Junko Itano; Hisao Higo; Kadoaki Ohashi; Go Makimoto; Kazuya Nishii; Katsuyuki Hotta; Nobuaki Miyahara; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Intern Med       Date:  2019-11-29       Impact factor: 1.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.